Involvement of 5-HT1A receptor-mediated histone acetylation in the regulation of depression.
8-Hydroxy-2-(di-n-propylamino)tetralin
/ administration & dosage
Acetylation
/ drug effects
Animals
Depression
/ drug therapy
Hippocampus
/ drug effects
Histone Deacetylase Inhibitors
/ administration & dosage
Histone Deacetylases
/ metabolism
Infusions, Intraventricular
Male
Mice
Mice, Inbred C57BL
Receptor, Serotonin, 5-HT1A
/ metabolism
Serotonin Receptor Agonists
/ administration & dosage
Journal
Neuroreport
ISSN: 1473-558X
Titre abrégé: Neuroreport
Pays: England
ID NLM: 9100935
Informations de publication
Date de publication:
11 08 2021
11 08 2021
Historique:
pubmed:
8
7
2021
medline:
28
1
2022
entrez:
7
7
2021
Statut:
ppublish
Résumé
Depression is one of the most common and disabling mental disorders. There is growing evidence that 5-HT1A receptor is involved in the regulation of depressive-related behaviors. However, the exact mechanism underlying the role of 5-HT1A receptor in depression remains unknown. Histone acetylation is associated with the pathophysiology and treatment of depression. In the current study, we investigated whether the epigenetic histone deacetylase (HDAC)-induced histone acetylation mediates the regulation of 5-HT1A receptor in depressive behaviors. We showed that 5-HT1A receptor selective agonist (±)-8-hydroxy-2-(dipropylamino) tetralin hydrobromide led to significant increase in acetylation of H3 at lysine 9 (Ac-H3K9) and H4 at lysine 5 (Ac-H4K5) and lysine 12 (Ac-H4K12) with obviously decreasing histone deacetylase 1 (HDAC1), histone deacetylase 2 (HDAC2), histone deacetylase 4 (HDAC4) and histone deacetylase 5 (HDAC5) expression in hippocampus of mice. Conversely, 5-HT1A receptor selective antagonist NAN-190 decreased the level of acetylation of H3 and H4 with increasing the expression of HDAC1, HDAC2, HDAC4 and HDAC5 in the hippocampus. Furthermore, we found that HDAC inhibitors, trichostatin A or suberoylanilide hydroxamic acid infusion to hippocampus prevented the depressive behaviors induced by NAN-190, as well as histone H3 and H4 acetylation in mice. Our results suggested that epigenetic histone acetylation coupled with 5-HT1A receptor may play vital role in the pathophysiology and treatment of depressive disorders.
Identifiants
pubmed: 34232131
doi: 10.1097/WNR.0000000000001693
pii: 00001756-202108020-00009
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Serotonin Receptor Agonists
0
Receptor, Serotonin, 5-HT1A
112692-38-3
8-Hydroxy-2-(di-n-propylamino)tetralin
78950-78-4
Histone Deacetylases
EC 3.5.1.98
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1049-1057Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Cui R. Editorial: a systematic review of depression. Curr Neuropharmacol. 2015; 13:480.
Smith K. Mental health: a world of depression. Nature. 2014; 515:181.
Latendresse G, Elmore C, Deneris A. Selective serotonin reuptake inhibitors as first-line antidepressant therapy for perinatal depression. J Midwifery Womens Health. 2017; 62:317–328.
Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 1996; 19:179–200.
Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Mol Brain. 2017; 10:28.
Garcia-Garcia AL, Newman-Tancredi A, Leonardo ED. 5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology (Berl). 2014; 231:623–636.
Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000; 57:174–180.
Misztak P, Pańczyszyn-Trzewik P, Sowa-Kućma M. Histone deacetylases (HDACs) as therapeutic target for depressive disorders. Pharmacol Rep. 2018; 70:398–408.
Covington HE 3rd, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett. 2011; 493:122–126.
Hobara T, Uchida S, Otsuki K, Matsubara T, Funato H, Matsuo K, et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res. 2010; 44:263–270.
Forsberg EC, Bresnick EH. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays. 2001; 23:820–830.
Grunstein M. Histone acetylation in chromatin structure and transcription. Nature. 1997; 389:349–352.
Zhu LJ, Shi HJ, Chang L, Zhang CC, Si M, Li N, Zhu DY. nNOS-CAPON blockers produce anxiolytic effects by promoting synaptogenesis in chronic stress-induced animal models of anxiety. Br J Pharmacol. 2020; 177:3674–3690.
Slattery DA, Cryan JF. Using the rat forced swim test to assess antidepressant-like activity in rodents. Nat Protoc. 2012; 7:1009–1014.
Chen D, Wang C, Li M, She X, Yuan Y, Chen H, et al. Loss of Foxg1 impairs the development of cortical SST-interneurons leading to abnormal emotional and social behaviors. Cereb Cortex. 2019; 29:3666–3682.
Zhu LJ, Li TY, Luo CX, Jiang N, Chang L, Lin YH, et al. CAPON-nNOS coupling can serve as a target for developing new anxiolytics. Nat Med. 2014; 20:1050–1054.
Boulle F, van den Hove DL, Jakob SB, Rutten BP, Hamon M, van Os J, et al. Epigenetic regulation of the BDNF gene: implications for psychiatric disorders. Mol Psychiatry. 2012; 17:584–596.
Racagni G, Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci. 2008; 10:385–400.
Fuchikami M, Yamamoto S, Morinobu S, Okada S, Yamawaki Y, Yamawaki S. The potential use of histone deacetylase inhibitors in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry. 2016; 64:320–324.
Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell. 2007; 128:635–638.
Kurdistani SK, Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol. 2003; 4:276–284.
Krämer OH, Göttlicher M, Heinzel T. Histone deacetylase as a therapeutic target. Trends Endocrinol Metab. 2001; 12:294–300.
Covington HE 3rd, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci. 2009; 29:11451–11460.
Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata H, Hobara T, et al. Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron. 2011; 69:359–372.
Sarkar A, Chachra P, Kennedy P, Pena CJ, Desouza LA, Nestler EJ, Vaidya VA. Hippocampal HDAC4 contributes to postnatal fluoxetine-evoked depression-like behavior. Neuropsychopharmacology. 2014; 39:2221–2232.
Ferland CL, Schrader LA. Regulation of histone acetylation in the hippocampus of chronically stressed rats: a potential role of sirtuins. Neuroscience. 2011; 174:104–114.
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006; 9:519–525.
Lesse A, Rether K, Gröger N, Braun K, Bock J. Chronic postnatal stress induces depressive-like behavior in male mice and programs second-Hit stress-induced gene expression patterns of OxtR and AvpR1a in adulthood. Mol Neurobiol. 2017; 54:4813–4819.
Nasca C, Zelli D, Bigio B, Piccinin S, Scaccianoce S, Nisticò R, McEwen BS. Stress dynamically regulates behavior and glutamatergic gene expression in hippocampus by opening a window of epigenetic plasticity. Proc Natl Acad Sci USA. 2015; 112:14960–14965.
Seo MK, Ly NN, Lee CH, Cho HY, Choi CM, Nhu LH, et al. Early life stress increases stress vulnerability through BDNF gene epigenetic changes in the rat hippocampus. Neuropharmacology. 2016; 105:388–397.
Samuels BA, Anacker C, Hu A, Levinstein MR, Pickenhagen A, Tsetsenis T, et al. 5-HT1A receptors on mature dentate gyrus granule cells are critical for the antidepressant response. Nat Neurosci. 2015; 18:1606–1616.
Walkinshaw DR, Tahmasebi S, Bertos NR, Yang XJ. Histone deacetylases as transducers and targets of nuclear signaling. J Cell Biochem. 2008; 104:1541–1552.
Gräff J, Tsai LH. The potential of HDAC inhibitors as cognitive enhancers. Annu Rev Pharmacol Toxicol. 2013; 53:311–330.
Broide RS, Redwine JM, Aftahi N, Young W, Bloom FE, Winrow CJ. Distribution of histone deacetylases 1-11 in the rat brain. J Mol Neurosci. 2007; 31:47–58.
Lesch KP, Waider J. Serotonin in the modulation of neural plasticity and networks: implications for neurodevelopmental disorders. Neuron. 2012; 76:175–191.